viewAlita Resources Ltd

Alliance Mineral Assets to list strategic placement shares on SGX Catalist

The placements will provide $32.5 million for continued upgrades to Alliance’s processing facilities and future exploration at the Ball Hill lithium and tantalum mine in WA.

Investment by Galaxy Resources and Jiangte

Alliance Mineral Assets Ltd’s (ASX:A40) (SGX:40F) new shares related to its recent placements will be listed on the Catalist Board of the Singapore Exchange (SGX-ST).

The new shares will be issued to Galaxy Resources Ltd (ASX:GXY) and a subsidiary of China-based Jiangxi Special Electric Motor Co (Jiangte).

READ: Alliance Mineral Assets Ltd enters strategic placements with Galaxy and Jiangte to raise $32.5 million

The institutional placement with Galaxy will comprise the issue of 112.5 million shares whereas Jiangte will receive 50 million through a conditional placement.

Both placements were not underwritten and were managed and arrangement by Canaccord Genuity who will be issued 6.125 million shares as placement fee.

The listing and quotation of the 168,625,000 new shares on the Catalist Board is subject to compliance with the SGX-ST’s listing requirements.


Alliance had notched up quarterly records for lithium production and shipping totals from the Bald Hill Lithium and Tantalum Mine in Western Australia.

Lithium production for the March 2019 quarter was 68% higher than the previous quarter with 38,291 wet metric tonnes (wmt) of high-grade spodumene concentrate produced grading 6.1% lithium carbonate.

Quick facts: Alita Resources Ltd

Price: - AUD

Market: ASX
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Algernon Pharmaceuticals begins screening patients for Phase 2 chronic cough...

Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has begun screening patients in Australia for a Phase 2 idiopathic pulmonary fibrosis and chronic cough clinical study with their repurposed drug...

26 minutes ago

2 min read